US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust NYSE Arca Biotechnology Index Fund

271.23

+3.391.26%

Volume:24.60K

Turnover:6.64M

Market Cap:2.94B

PE:31.74

High:273.09

Open:267.37

Low:267.37

Close:267.84

52wk High:274.81

52wk Low:173.87

Shares:10.85M

Float Shares:10.85M

Volume Ratio:0.99

T/O Rate:0.23%

Dividend:- -

Dividend Rate:- -

EPS(TTM):8.55

EPS(LYR):37.75

ROE:19.96%

ROA:-0.16%

PB:2.22

PE(LYR):7.18

Loading ...

Overview Company News Filings

Neogenomics Inc: Decrease in Operating Expenses for Q2 2026 was Primarily Due to $20 Mln of Impairment Charges Taken in Q2 2025

THOMSON REUTERS

Neogenomics Q2 Operating Expenses USD 102 Million

THOMSON REUTERS

Neogenomics: Sees Fy2026 Adj Ebitda $56 Mln to $58 MLN\n

THOMSON REUTERS

Neogenomics: Expects Fy2026 Net Loss of $42 Mln to $34 MLN\n

THOMSON REUTERS

Neogenomics Q2 Adjusted Ebitda USD 14 Million

THOMSON REUTERS

Neogenomics Reports Second Quarter 2026 Results

THOMSON REUTERS

Veracyte to Participate in Upcoming Investor Conferences

Wall Street Analysts Are Bullish on Top Healthcare Picks

Alkermes Price Target Raised to $65.00/Share from $43.00 by Piper Sandler

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS) and Universal Health (UHS)

Alkermes Plc Reports Results for the Quarter Ended June 30 - Earnings Summary

Alkermes Releases Transcript of Q2 2026 Earnings Call

Alkermes sinks 5% to $50.05 following Q2 report

Alkermes Q2 Earnings Flat, Revenue Rises; Reiterates 2026 Revenue Guidance

MT Newswires Live

Alkermes Q2 Sales $496.009M Beat $457.818M Estimate

Benzinga Earnings

Press Release: Alkermes Plc Reports Second Quarter 2026 Financial Results

Alkermes Plc : Piper Sandler Raises Target Price to $65 from $43

THOMSON REUTERS

Press Release: NEO Battery Reports Fiscal Year 2027 First Quarter Results

Oppenheimer would own Capricor Therapeutics into committee meeting

Pacira transitions PCRX-201 to a U.S.-based manufacturing process

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/FBT/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FBT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","market":"US","secType":"STK","nameCN":"First Trust NYSE Arca Biotechnology Index Fund","latestPrice":271.225,"timestamp":1788371118652,"preClose":267.84,"halted":0,"volume":24595,"delay":0,"changeRate":0.012638142174432676,"floatShares":10850002,"shares":10850002,"eps":8.545272,"marketStatus":"Trading","change":3.385,"latestTime":"09-02 13:45:34 EDT","open":267.37,"high":273.0901,"low":267.37,"amount":6641380.4715,"amplitude":0.021356,"askPrice":271.65,"askSize":103,"bidPrice":271.41,"bidSize":22,"shortable":3,"etf":1,"ttmEps":8.545272,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":267.84,"sharesOutstanding":11450002,"nav":267.27,"aum":2913243534.54,"bidAskSpread":0.001063,"preHourTrading":{"tag":"盘前","latestPrice":267.96,"preClose":267.84,"latestTime":"07:52 EDT","volume":5,"amount":1334.34,"timestamp":1788349977151,"change":0.12,"changeRate":0.000448,"amplitude":0.000448},"postHourTrading":{"tag":"盘后","latestPrice":267.84,"preClose":267.84,"latestTime":"19:44 EDT","volume":19,"amount":5092.48,"timestamp":1788306289404,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.994056,"impliedVol":0.2022,"impliedVolPercentile":0.4167},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","floatShares":10850002,"roa":"-0.16%","roe":"19.96%","lyrEps":37.754725,"volumeRatio":0.994056,"shares":10850002,"dividePrice":0,"high":273.0901,"amplitude":0.021356,"preClose":267.84,"low":267.37,"week52Low":173.8701,"pbRate":"2.22","psRate":"1083.55","week52High":274.81,"institutionHeld":0,"latestPrice":271.225,"committee":-0.648,"eps":8.545272,"divideRate":0,"volume":24595,"delay":0,"ttmEps":8.545272,"open":267.37,"prevYearClose":206.52,"prevWeekClose":266.95,"prevMonthClose":267.15,"prevQuarterClose":247.89,"fiveDayClose":272.07,"twentyDayClose":249,"sixtyDayClose":221.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBT\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FBT","amount":1.1726,"announcedDate":"2024-12-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"First Trust NYSE Arca Biotechnology Index Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"},{"market":"US","date":"2022-01-10","symbol":"FBT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1641790800000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2021-12-30","symbol":"FBT","amount":2.2136,"defaultRemindTime":1640874600000,"name":"First Trust NYSE Arca Biotechnology Index Fund","recordDate":"2022-01-10","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBT\",market:\"US\",,,undefined,":[{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-10","value":2.2136,"currency":"USD"},{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":1.1726,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBT\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2655988083","title":"Neogenomics Inc: Decrease in Operating Expenses for Q2 2026 was Primarily Due to $20 Mln of Impairment Charges Taken in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2655988083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655988083?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:05","pubTimestamp":1785269101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nPLX2GZQJX:12","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","LU0012050646.USD","BK4196","LU0106261612.USD","FBT","NEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872548","title":"Neogenomics Q2 Operating Expenses USD 102 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655872548?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:05","pubTimestamp":1785269101,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nPLX2GZQJX:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","BK4121","FBT","LU0012050646.USD","NEO","LU0106261612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655746887","title":"Neogenomics: Sees Fy2026 Adj Ebitda $56 Mln to $58 MLN\\n","url":"https://stock-news.laohu8.com/highlight/detail?id=2655746887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655746887?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:05","pubTimestamp":1785269101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nPLX2GZQJX:8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","LU0012050646.USD","BK4196","FBT","LU0106261612.USD","NEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655704887","title":"Neogenomics: Expects Fy2026 Net Loss of $42 Mln to $34 MLN\\n","url":"https://stock-news.laohu8.com/highlight/detail?id=2655704887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655704887?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:05","pubTimestamp":1785269101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nPLX2GZQJX:9","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","LU0106261612.USD","BK4196","LU0012050646.USD","NEO","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655450887","title":"Neogenomics Q2 Adjusted Ebitda USD 14 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655450887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655450887?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:05","pubTimestamp":1785269101,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nPLX2GZQJX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEO","LU0106261612.USD","BK4196","FBT","BK4121","LU0012050646.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655887147","title":"Neogenomics Reports Second Quarter 2026 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2655887147","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655887147?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:05","pubTimestamp":1785269101,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nTUAK3WCS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEO","BK4196","LU0012050646.USD","FBT","BK4121","LU0106261612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655836870","title":"Veracyte to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2655836870","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655836870?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:05","pubTimestamp":1785269100,"startTime":"0","endTime":"0","summary":"Kelly Gura. investors@veracyte.com. Media:. Molly Cornbleet. media@veracyte.com. +1-650-351-8780","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/28/3334706/0/en/Veracyte-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VCYT","FBT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655884804","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2655884804","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655884804?lang=en_us&edition=fundamental","pubTime":"2026-07-29 02:00","pubTimestamp":1785261615,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alkermes (ALKS) and Incyte (INCY) with bullish senti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-264?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-264?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","IBRN","BK4550","PSIL","BK4139","ALKS","BK4532","MEDX","INCY","PSCH","BK4585","BK4588","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655264886","title":"Alkermes Price Target Raised to $65.00/Share from $43.00 by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2655264886","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655264886?lang=en_us&edition=fundamental","pubTime":"2026-07-29 00:10","pubTimestamp":1785255000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALKS/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALKS","PSCH","FBT","MEDX","PSIL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654424888","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS) and Universal Health (UHS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654424888","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654424888?lang=en_us&edition=fundamental","pubTime":"2026-07-28 22:20","pubTimestamp":1785248424,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alkermes (ALKS) and Universal Health (UHS). Alkermes (ALKS) Needh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-alkermes-alks-and-universal-health-uhs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-alkermes-alks-and-universal-health-uhs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4185","XLV","LU0128526141.USD","BK4588","BK4585","FBT","BK4581","IBRN","MEDX","BK4137","BK4139","HCSG","LABU","ALKS","PSIL","UHS","PSCH","XBI","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654700086","title":"Alkermes Plc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2654700086","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654700086?lang=en_us&edition=fundamental","pubTime":"2026-07-28 21:32","pubTimestamp":1785245569,"startTime":"0","endTime":"0","summary":"Alkermes Plc reports results for the quarter ended June 30 - Earnings SummaryAlkermes PlcALKS.OQreported quarterly breakeven results per share for the quarter ended June 30, lower than the same quarte","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nL8N43U1WO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","FBT","BK4139","ALKS","MEDX","PSIL","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654071550","title":"Alkermes Releases Transcript of Q2 2026 Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2654071550","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654071550?lang=en_us&edition=fundamental","pubTime":"2026-07-28 21:17","pubTimestamp":1785244649,"startTime":"0","endTime":"0","summary":"Alkermes releases transcript of Q2 2026 earnings callAlkermes discussed Q2 2026 results on an earnings call attended by CEO Richard Pops, CFO Joshua Reed, CCO Todd Nichols, COO and incoming CEO Blair ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL35dZmZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","IBRN","MEDX","PSCH","PSIL","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654007833","title":"Alkermes sinks 5% to $50.05 following Q2 report","url":"https://stock-news.laohu8.com/highlight/detail?id=2654007833","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654007833?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:50","pubTimestamp":1785243027,"startTime":"0","endTime":"0","summary":"08:45 EDT Alkermes (ALKS) sinks 5% to $50.05 following Q2 report Published first on TheFly – the ultimate source for real-time, market-moving break...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkermes-sinks-5-to-50-05-following-q2-report-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkermes-sinks-5-to-50-05-following-q2-report-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBRN","PSIL","MEDX","PSCH","FBT","BK4139","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654100907","title":"Alkermes Q2 Earnings Flat, Revenue Rises; Reiterates 2026 Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2654100907","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654100907?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:42","pubTimestamp":1785238953,"startTime":"0","endTime":"0","summary":"Alkermes  reported break-even earnings for Q2 Tuesday, compared with earnings of $0.52 per share a year earlier.Analysts polled by FactSet expected a loss of $0.03.Total revenue for the quarter ended June 30 was $496 million, up from $390.7 million a year earlier.Analysts surveyed by FactSet expected $457.4 million.For 2026, Alkermes reiterated its total revenue guidance of $1.73 billion to $1.84 billion. Analysts polled by FactSet expected $1.81 billion.Shares of the company were up less than 1% in recent Tuesday premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ALKS","MEDX","PSCH","PSIL","IBRN","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654006162","title":"Alkermes Q2 Sales $496.009M Beat $457.818M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2654006162","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654006162?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:02","pubTimestamp":1785236572,"startTime":"0","endTime":"0","summary":"Alkermes (NASDAQ:ALKS) reported quarterly sales of $496.009 million which beat the analyst consensus estimate of $457.818 million by 8.34 percent.  This is a 26.97 percent increase over sales of $390.657 million the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/07/60719288/alkermes-q2-sales-496-009m-beat-457-818m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","FBT","PSIL","MEDX","ALKS","PSCH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654006923","title":"Press Release: Alkermes Plc Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2654006923","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654006923?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:00","pubTimestamp":1785236400,"startTime":"0","endTime":"0","summary":"DUBLIN--(BUSINESS WIRE)--July 28, 2026--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press releas","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","FBT","MEDX","PSCH","ADHD","ALKS","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654502005","title":"Alkermes Plc : Piper Sandler Raises Target Price to $65 from $43","url":"https://stock-news.laohu8.com/highlight/detail?id=2654502005","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654502005?lang=en_us&edition=fundamental","pubTime":"2026-07-28 12:05","pubTimestamp":1785211555,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43T1LE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","IBRN","ALKS","PSIL","FBT","BK4139","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654202354","title":"Press Release: NEO Battery Reports Fiscal Year 2027 First Quarter Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2654202354","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654202354?lang=en_us&edition=fundamental","pubTime":"2026-07-28 04:45","pubTimestamp":1785185100,"startTime":"0","endTime":"0","summary":"TORONTO, July 27, 2026 /CNW/ -- NEO Battery Materials Ltd.   , a low-cost, silicon-enhanced battery manufacturer enabling high-performance capabilities for drones, robotics, and physical AI, today announced its financial and operational results for the first quarter ended May 31, 2026. All amounts are in Canadian dollars unless otherwise specified.\"NEO is adding momentum from the increasing global requirements for high-performance, non-Chinese and Foreign Entities of Concern  battery products and solutions and is highly focused on expanding business opportunities with battery materials and cell developers, drone/unmanned aerial vehicle  manufacturers, and robotics companies,\" stated Mr. Spencer Huh, President & CEO of NEO. \"We are first steadily building out the Korean drone OEM pipeline with customers and qualified leads by implementing a collaborative approach from product development, testing/validation, and feedback-based optimization. Due to elevated interest in Korean, high-quali","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0057025933.USD","LU0124676726.USD","LU0106261612.USD","BK4116","ROK","LU0154245673.USD","LU0689626769.HKD","CM","KC","BK4563","FBT","LU0012050646.USD","LU0154245756.USD","BK4196","BK4207","LU0069063385.USD","LU0511384066.AUD","LU1064131342.USD","UAV","LU1894683264.USD","BK4607","BK4121","LU0289961442.SGD","LU1988902786.USD","BK4585","BK4096","BK4580","BK4608","NEO","LU0472753341.HKD","BK4588","LU1894683348.USD","BK4526","LU2264538146.SGD","LU0289739343.SGD","LU0390134368.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654045069","title":"Oppenheimer would own Capricor Therapeutics into committee meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2654045069","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654045069?lang=en_us&edition=fundamental","pubTime":"2026-07-27 22:20","pubTimestamp":1785162008,"startTime":"0","endTime":"0","summary":"After briefing documents for this Wednesday’s FDA advisory committee for deramiocel became available this morning, Oppenheimer analyst Leland Gersh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oppenheimer-would-own-capricor-therapeutics-into-committee-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oppenheimer-would-own-capricor-therapeutics-into-committee-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","SBIO","BK4139","LABU","BBP","BK4127","BK4585","BBH","FBT","XBIX","BK4588","CAPR","IBRN","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654010362","title":"Pacira transitions PCRX-201 to a U.S.-based manufacturing process","url":"https://stock-news.laohu8.com/highlight/detail?id=2654010362","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654010362?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:10","pubTimestamp":1785154247,"startTime":"0","endTime":"0","summary":"Pacira (PCRX) announced that it has successfully transitioned PCRX-201, its investigational locally administered gene therapy for osteoarthritis of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pacira-transitions-pcrx-201-to-a-u-s-based-manufacturing-process-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pacira-transitions-pcrx-201-to-a-u-s-based-manufacturing-process-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","PCRX","GNOM","BK4007","CNCR","IBB","FBT","EES","LFSC","IBBQ","SYNB","TBXU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}